UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein

Journal of Nuclear Medicine, 2018-09, Vol.59 (9), p.1415-1422

2018

Link zum Volltext

Verfügbarkeit prüfen

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

British journal of cancer, 2018-11, Vol.119 (10), p.1208-1214

2018

Link zum Volltext

Verfügbarkeit prüfen

Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development

Journal of hematology and oncology, 2018-09, Vol.11 (1), p.120-11, Article 120

2018

Link zum Volltext

Verfügbarkeit prüfen

Far-Red and Near-IR AIE-Active Fluorescent Organic Nanoprobes with Enhanced Tumor-Targeting Efficacy: Shape-Specific Effects

Angewandte Chemie (International ed.), 2015-06, Vol.54 (25), p.7275-7280

International ed. in English, 2015

Link zum Volltext

Verfügbarkeit prüfen

Predictive Performance of Physiologically Based Pharmacokinetic (PBPK) Modeling of Drugs Extensively Metabolized by Major Cytochrome P450s in Children

Clinical pharmacology and therapeutics, 2018-07, Vol.104 (1), p.188-200

2018

Link zum Volltext

Verfügbarkeit prüfen

Anlotinib: First Global Approval

Drugs (New York, N.Y.), 2018-07, Vol.78 (10), p.1057-1062

Syed, Yahiya Y.

2018

Link zum Volltext

Verfügbarkeit prüfen

A novel multiple-stage antimalarial agent that inhibits protein synthesis

Nature (London), 2015-06, Vol.522 (7556), p.315-320

2015

Link zum Volltext

Verfügbarkeit prüfen

Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma

Clinical cancer research, 2016-03, Vol.22 (6), p.1385-1394

2016

Link zum Volltext

Verfügbarkeit prüfen

A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma

Neuro-oncology (Charlottesville, Va.), 2016-08, Vol.18 (8), p.1146-1156

2016

Link zum Volltext

Verfügbarkeit prüfen

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

Molecular cancer therapeutics, 2008-07, Vol.7 (7), p.1851-1863

2008

Link zum Volltext

Verfügbarkeit prüfen

The Discovery of I‑BET726 (GSK1324726A), a Potent Tetrahydroquinoline ApoA1 Up-Regulator and Selective BET Bromodomain Inhibitor

Journal of medicinal chemistry, 2014-10, Vol.57 (19), p.8111-8131

2014

Link zum Volltext

Verfügbarkeit prüfen

Discovery of Orally Bioavailable, Quinoline-Based Aldehyde Dehydrogenase 1A1 (ALDH1A1) Inhibitors with Potent Cellular Activity

Journal of medicinal chemistry, 2018-06, Vol.61 (11), p.4883-4903

2018

Link zum Volltext

Verfügbarkeit prüfen

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

Drug design, development and therapy, 2015-01, Vol.9 (default), p.4479-4499

2015

Link zum Volltext

Verfügbarkeit prüfen

Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial

The Lancet infectious diseases, 2013, Vol.13 (1), p.27-35

2013

Link zum Volltext

Verfügbarkeit prüfen

Neuroprotection of brain-permeable iron chelator VK-28 against intracerebral hemorrhage in mice

Journal of cerebral blood flow and metabolism, 2017-09, Vol.37 (9), p.3110-3123

2017

Link zum Volltext

Verfügbarkeit prüfen

Design, Synthesis, and Evaluation of Orally Bioavailable Quinoline–Indole Derivatives as Innovative Multitarget-Directed Ligands: Promotion of Cell Proliferation in the Adult Murine Hippocampus for the Treatment of Alzheimer’s Disease

Journal of medicinal chemistry, 2018-03, Vol.61 (5), p.1871-1894

2018

Link zum Volltext

Verfügbarkeit prüfen

Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure–Response Analyses

Journal of clinical pharmacology, 2017-09, Vol.57 (9), p.1138-1147

2017

Link zum Volltext

Verfügbarkeit prüfen

First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours

British journal of cancer, 2020-12, Vol.123 (12), p.1730-1736

2020

Link zum Volltext

Verfügbarkeit prüfen

Cerebrospinal Fluid Clearance in Alzheimer Disease Measured with Dynamic PET

Journal of Nuclear Medicine, 2017-09, Vol.58 (9), p.1471-1476

2017

Link zum Volltext

Verfügbarkeit prüfen

Quantitative Analyses of Hepatic OATP-Mediated Interactions Between Statins and Inhibitors Using PBPK Modeling With a Parameter Optimization Method

Clinical pharmacology and therapeutics, 2016-11, Vol.100 (5), p.513-523

2016

Link zum Volltext

Verfügbarkeit prüfen

Safety, Pharmacokinetics, and Mosquito‐Lethal Effects of Ivermectin in Combination With Dihydroartemisinin‐Piperaquine and Primaquine in Healthy Adult Thai Subjects

Clinical pharmacology and therapeutics, 2020-05, Vol.107 (5), p.1221-1230

2020

Link zum Volltext

Verfügbarkeit prüfen

Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer

Journal for immunotherapy of cancer, 2021-03, Vol.9 (3), p.e002068

2021

Link zum Volltext

Verfügbarkeit prüfen

The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1,3-dihydro-2 H-imidazo[4,5- c]quinolin-2-one)

Journal of medicinal chemistry, 2018-05, Vol.61 (9), p.3823-3841

2018

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic/Pharmacodynamic (PK/PD) Indices of Antibiotics Predicted by a Semimechanistic PKPD Model: a Step toward Model-Based Dose Optimization

Antimicrobial Agents and Chemotherapy, 2011-10, Vol.55 (10), p.4619-4630

2011

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic Evaluation of the Penetration of Antituberculosis Agents in Rabbit Pulmonary Lesions

Antimicrobial Agents and Chemotherapy, 2012-01, Vol.56 (1), p.446-457

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.774

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.662)
Mit Volltextzugriff
(1.444)

Publikationsform

Sprache

8 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.554)
Life Sciences & Biomedicine
(1.505)
Humans
(1.252)
Quinolines - Pharmacokinetics
(1.178)
Pharmacology & Pharmacy
(958)
Male
(881)
Animals
(824)
Biological And Medical Sciences
(760)
Medical Sciences
(736)
Female
(603)
Pharmacology. Drug Treatments
(584)
Quinolines - Pharmacology
(567)
Adult
(454)
Quinolines - Administration & Dosage
(446)
Pharmacokinetics
(402)
Rats
(363)
Middle Aged
(361)
Fluoroquinolones
(349)
Quinolines - Therapeutic Use
(306)
Pharmacology
(276)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development

Far-Red and Near-IR AIE-Active Fluorescent Organic Nanoprobes with Enhanced Tumor-Targeting Efficacy: Shape-Specific Effects

Predictive Performance of Physiologically Based Pharmacokinetic (PBPK) Modeling of Drugs Extensively Metabolized by Major Cytochrome P450s in Children

Anlotinib: First Global Approval

A novel multiple-stage antimalarial agent that inhibits protein synthesis

Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma

A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

The Discovery of I‑BET726 (GSK1324726A), a Potent Tetrahydroquinoline ApoA1 Up-Regulator and Selective BET Bromodomain Inhibitor

Discovery of Orally Bioavailable, Quinoline-Based Aldehyde Dehydrogenase 1A1 (ALDH1A1) Inhibitors with Potent Cellular Activity

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial

Neuroprotection of brain-permeable iron chelator VK-28 against intracerebral hemorrhage in mice

Design, Synthesis, and Evaluation of Orally Bioavailable Quinoline–Indole Derivatives as Innovative Multitarget-Directed Ligands: Promotion of Cell Proliferation in the Adult Murine Hippocampus for the Treatment of Alzheimer’s Disease

Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure–Response Analyses

First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours

Cerebrospinal Fluid Clearance in Alzheimer Disease Measured with Dynamic PET

Quantitative Analyses of Hepatic OATP-Mediated Interactions Between Statins and Inhibitors Using PBPK Modeling With a Parameter Optimization Method

Safety, Pharmacokinetics, and Mosquito‐Lethal Effects of Ivermectin in Combination With Dihydroartemisinin‐Piperaquine and Primaquine in Healthy Adult Thai Subjects

Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer

The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1,3-dihydro-2 H-imidazo[4,5- c]quinolin-2-one)

Pharmacokinetic/Pharmacodynamic (PK/PD) Indices of Antibiotics Predicted by a Semimechanistic PKPD Model: a Step toward Model-Based Dose Optimization

Pharmacokinetic Evaluation of the Penetration of Antituberculosis Agents in Rabbit Pulmonary Lesions

Suchergebnisse filtern